Credit Analysis and Research scrip shines after strong Q1FY17

Credit Analysis and Research (CARE) has declared its Q1FY17 results on Friday. The company’s revenue has increased by 18 per cent to Rs 57.15 crore in Q1FY17 on a yearly basis. Its EBITDA too has  risen by 39.4 per cent to Rs 37.75 crore in Q1FY17 as compared to same period in previous fiscal. CARE’s EBITDA margin has expanded by 1060 basis points to 63.3 per cent in Q1FY17 on a yearly basis.

The company’s PAT has boosted by 41.1 per cent to Rs 24.67 crore in Q1FY17 as compared to same period in previous financial year. Its PAT margin has expanded by 700 basis points to 41.4 per cent in Q1FY17 on a yearly basis. CARE has 12127 active clients as of June 2016. The company has rated around 1325 instruments and has resorted to the rating of debt of Rs 3.78 lakh crore during Q1FY17.

The share price of CARE has increased by 10.48 per cent on bourses in early trades; and is trading at Rs 1165 on an intraday basis.

CARE is engaged in financial services other than securities dealing activities. It provides credit rating that helps the corporates to raise capital for their various requirements and assists the investors to form an investment decision based on the credit risk and their own risk-return expectations. The company’s market segments include corporates; financial sector; public financial; project finance and infrastructure.